Millennium Pharmaceuticals Limited

Cornell University

Tri-Institutional Therapeutics Discovery Institute

Takeda Pharmaceutical Company Limited

Other

Tzu-Tshin Wong

Paul E Fleming

Francois Soucy

Jeffrey P Ciavarri

Yingchun Ye

Indu T Bharathan

Mario Girard

Gang Herbert Lin

Steven P Langston

Carl F Nathan

Toshihiro Imaeda

Kenjiro Sato

Rei Okamoto

Michael Andrew Foley

Kazuyoshi Aso

Jeffrey L Gaulin

Wenhu Zhan

Roushan Afroze

Trevor Morgan

Ryoma Hara

Stephen G Stroud

Tricia J Vos

He Xu

Yongbo Hu

Gang Li

Kenneth M Gigstad

Courtney A Cullis

Michael D Sintchak

Tianlin Xu

Chris Blackburn

Krista E Gipson

Janice Lee

Mansoureh Rezaei

Jouhara Chouitar

Natalie D'Amore

Takuto Kojima

Shinichi Imamura

Yasutomi Asano

Shuji Kitamura

Yasufumi Miyamoto

Yasuhiro Hirata

Yuta Tanaka

Osamu Kurasawa

Takafumi Yukawa

Kazuko Yonemori

Akinori Toita

Naoki Iwamura

Laura Kirkman

Ryosuke Arai

Bunnai Saito

Osamu Sano

Masanori Kawasaki

John D Ginn

Marlo Girard

Arai Ryosuke

Francois R Soucy

Natalie D'amore

The compounds of the present invention are represented by the following compounds having Formula I and Formula (I′): where the substituents R, R, R, R, R, R, R', R″, X, Y, and Z are as defined herein and where the substituents R, R, R, R, R, R', R″, X, Y, and Z are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues.

Macrocyclic compounds as proteasome inhibitors

The compounds of the present invention are represented by the following compounds having Formula I and Formula (I'): where the substituents R, R, R, R, R, R, R&#x2032;, R&#x2033;, X, Y, and Z are as defined herein and where the substituents R, R, R, R, R, R&#x2032;, R&#x2033;, X, Y, and Z are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues.

The compounds of the present invention are represented by the following compounds having Formula (I) and Formula (I'): where the substituents R, R, R, R, R, W, X, Y, Z, k, and m are as defined herein and where the substituents R, R, R, R, R, X, Y, Z, and m are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues.

Peptidomimetic proteasome inhibitors

The compounds of the present invention are represented by the following compounds having Formula (I) and Formula (I'): where the substituents R, R, RR, R&#x2032;, W, X, Y, Z, k, and m are as defined herein and where the substituents R, R, R, R, R, X, Y, Z, and m are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues. 

The present invention provides a compound of formula I: and pharmaceutically acceptable salts thereof, wherein X, R, R, R, R, R, L, L, m, and n, are as described in the specification. Such compounds are inhibitors of VPS34 and thus useful for treating proliferative, inflammatory, or cardiovascular disorders.

Heteroaryls and uses thereof

The present invention relates to a compound which can be useful for the treatment or prevention of SPT-related diseases including cancer and congenital diseases associated with sphingolipid accumulation (including Niemann-Pick disease).

Heterocyclic compound

Disclosed are chemical entities that inhibit ubiquitin-activating enzyme (UAE), each of which is a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein Y is and W, Z, X, R, Rand Rare defined herein; pharmaceutical compositions comprising the chemical entities; and methods of using the chemical entities. These chemical entities are useful for treating disorders, particularly cell proliferation disorders, including cancers.

Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme

Growing community of inventors

Acton, MA, United States of America

Tzu-Tshin Wong